Localized prostate cancer treated with intensity-modulated radiotherapy

Tumori

Volumn 92, Issue 3, 2006, Pages 197-201

  Livi, Lorenzo ^a   Paiar, Fabiola ^a   Banci Buonamici, Fabrizio ^a   Simontacchi, Gabriele ^a   Detti, Beatrice ^a   Gacci, Mauro ^a   Mondaini, Nicola ^a   Nelli, Federico ^a   Bastiani, Paolo ^a   Pertici, Maurizio ^a   Mungai, Raffaello ^a   Ponticelli, Pietro ^b   Biti, Giampaolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Cancer Registry and Human Pathology Department   (Italy)

Author keywords

Intensity modulated radiotherapy; Prostate cancer; Radiotherapy treatment

Indexed keywords

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; FEASIBILITY STUDY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RADIATION DOSE; RECTUM DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT DISEASE;

EID: 33746268368     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200302     Document Type: Article

References (31)

1. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys, 41: 491-500, 1998.
2. Hanks GE, Hanlon AL, Pinover WH, Horwitz EM, Price RA, Schultheiss T: Dose selection for prostate cancer based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys, 46: 823-832, 2000.
3. Magrini SM, Cellai E, Pertici M, Rossi F, Ponticelli P, Odantini R, Cappellini M, Biti GP: Radical radiotherapy of localised prostate cancer: the relationship between radiation dose and survival. Cancer Radiother, 2: 351-358, 1998.
4. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol, 166: 1839, 2001.
5. Corn BW, Hanks GE, Schultheiss TE, Hunt MA, Lee WR, Coia LR: Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. Int J Radiat Oncol Biol Phys, 32: 325-330, 1995.
6. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA: Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol, 13: 464-469, 1995.
7. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sause WT, Doggett SR: Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys, 21: 935-939, 1991.
8. Michalski JM, Purdy JA, Winter K, Roach M, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD: Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys, 46: 391-402, 2000.
9. Foppiano F, Fiorino C, Frezza G, Greco C, Valdagni R, AIRO National Working Group on Prostate Radiotherapy: The impact of contouring uncertainty on rectal 3D dose-volume data: results of a dummy run in a multicenter trial (AIRO-PROS01-02). Int J Radiat Oncol Biol Phys, 57: 573-579, 2003.
10. Michalski JM, Winter K, Purdy JA, Wilder RB, Perez CA, Roach M, Parliament MB, Pollack A, Markoe AM, Harms W, Sandler HM, Cox JD: Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys, 56: 192-198, 2003.
11. Boehmer D, Bohsung J, Eichwurzel I, Moys A, Budach V: Clinical and physical quality assurance for intensity modulated radiotherapy of prostate cancer. Radiother Oncol, 71: 319-325, 2004.
12. Kuban D, Pollack A, Huang E, Levy L, Dong L, Starkschall G, Rosen I: Hazards of dose escalation in prostate Cancer radiotherapy. Int J Radiat Oncol Biol Phys, 57: 1260-1268, 2003.
13. Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I, Kuban DA: Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 54: 1314-1321, 2002.
14. Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, Piazzolla A, Vavassori V, Valdagni R: Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys, 57: 953-962, 2003.
15. Bucciolini M, Banci Buonamici F, Casati M: Verification of IMRT fields by film dosimetry. Med Phys, 31: 161-168, 2004.
16. Emani B, Lyman J, Brown A, Coia L, Goitein M, Munzerider JE, Shank B, Solin LJ, Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys, 21: 109-122, 1991.
17. Lyman JT: Complication probability as assessed from dose-volume histograms. Radiat Res Suppl, 104: 13-19, 1985.
18. Kutcher GJ, Burman C: Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys, 16: 1623-1630, 1989.
19. Burman C, Kutcher G J, Emami B, Goitein M: Fitting of normal tissue tolerance data to an analytic function. Int J Radiat Oncol Biol Phys, 21: 123-135, 1991.
20. Nutting CM, Corbishley CM, Sanchez-Nieto B, Cosgrove VP, Webb S, Dearnaley DP: Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br J Radiol, 75: 151-161, 2002.
21. Teh BS, Woo SY, Butler EB: Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology. Oncologist, 4: 433-442, 1999.
22. De Meerleer G, Vakaet L, Meersschout S, Villeirs G, Verbaeys A, Oosterlinck W, De Neve W: Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys, 60: 777-787, 2004.
23. Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, Hunt M, Wolfe T, Venkatraman ES, Jackson A, Skwarchuk M, Leibel SA: Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol, 55: 241-249, 2000.
24. Peeters ST, Heemsbergen WD, van Putten WL, Slot A, Tabak H, Mens JW, Lebesque JV, Koper PC: Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys, 61: 1019-1034, 2005.
25. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA: High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys, 53: 1111-1116, 2002.
26. Leibel SA, Zelefsky MJ, Kutcher GJ, Burman CM, Kelson S, Fuks Z: Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study. J Urol, 152: 1792-1798, 1994.
27. Magrini SM, Bertoni F, Vavassori V, Villa S, Cagna E, Maranzano E, Pertici M, Pradella R, Spediacci MA, Chiavacci A, Ambrosi E, Livi L, Magli A, Bellavita R, Bossi A, Biti G: Practice patterns for prostate cancer in nine central and northern Italy radiation oncology centers: a survey including 1759 patients treated during two decades (1980-1998). Int J Radiat Oncol Biol Phys, 52: 1310-1319, 2002.
28. Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D: Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys, 61: 993-1002, 2005.
29. Lyons JA, Kupelian PA, Mohan DS, Reddy CA, Klein EA: Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology, 55: 85, 2000.
30. Pollack A, Zagars GK: External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys, 39: 1011-1018, 1997.
31. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I: Preliminary results of a randomized radiotherapy dose escalation study comparing 70 Gy to 78 Gy for prostate cancer. J Clin Oncol, 18: 3904, 2000.